Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by investment analysts at BMO Capital Markets in a note issued to investors on Friday. They currently have a $160.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $221.00. BMO Capital Markets’ price target points to a potential upside of 159.78% from the company’s current price.

Other research analysts also recently issued reports about the company. Cowen and Company reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Credit Suisse Group set a $201.00 price objective on Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 3rd. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC restated a “buy” rating and issued a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. Finally, Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target for the company in a research note on Tuesday, July 11th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $174.93.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded down 16.43% during midday trading on Friday, hitting $61.59. 11,875,646 shares of the stock were exchanged. The stock’s market cap is $1.55 billion. Intercept Pharmaceuticals has a 52-week low of $60.97 and a 52-week high of $172.95. The firm’s 50 day moving average price is $106.75 and its 200-day moving average price is $115.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s revenue was up 459.6% on a year-over-year basis. During the same period in the previous year, the company posted ($3.14) EPS. On average, equities research analysts expect that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/23/intercept-pharmaceuticals-inc-icpt-price-target-lowered-to-160-00-at-bmo-capital-markets.html.

In related news, Director Daniel G. Welch sold 602 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $123.93, for a total transaction of $74,605.86. Following the sale, the director now owns 3,108 shares in the company, valued at approximately $385,174.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the sale, the director now owns 3,710 shares in the company, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders have sold a total of 48,013 shares of company stock worth $6,198,747 over the last ninety days. Insiders own 9.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. raised its holdings in Intercept Pharmaceuticals by 100.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after buying an additional 15,000 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Intercept Pharmaceuticals by 9.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 178 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Intercept Pharmaceuticals during the 1st quarter valued at $414,000. Geode Capital Management LLC raised its holdings in Intercept Pharmaceuticals by 12.8% during the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after buying an additional 16,392 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Intercept Pharmaceuticals by 9.2% during the 1st quarter. Van ECK Associates Corp now owns 25,550 shares of the biopharmaceutical company’s stock valued at $2,890,000 after buying an additional 2,161 shares during the period. Institutional investors own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.